Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.58

-0.1%

Dec 10 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	4/1/2002 2:07:22 PM
From: IRWIN JAMES FRANKEL	Read Replies (2) of 52153

13:26 ET BGEN Biogen: Fulcrum expects negative FDA recommendation on Amevive (47.74 -1.32) Fulcrum believes that Sell-rated BGEN will receive a negative FDA Advisory Committee panel recommendation on May 23 for Amevive; firm believes that the co will not be able to demonstrate to the satisfaction of the panel that Amevive does not increase risk for basal cell and squamous cell carcinoma and that it does not significantly increase the patient's risk for other infections; also, the FDA is expected to take extra caution on new drugs for autoimmune disease in general, and that competing drugs by DNA, IDPH, and MEDX may be safer for the immune system.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next